Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma

Abstract EN

Cutaneous T-cell lymphoma (CTCL) is the most frequently encountered type of skin lymphoma in humans.

CTCL encompasses multiple variants, but the most common types are mycosis fungoides (MF) and Sezary syndrome (SS).

While most cases of MF run a mild course over a period of many years, other subtypes of CTCL are very aggressive.

The rapidly expanding fields of proteomics and genomics have not only helped increase knowledge concerning the carcinogenesis and tumor biology of CTCL but also led to the discovery of novel markers for targeted therapy.

Although multiple biomarkers linked to CTCL have been known for a relatively long time (e.g., CD25, CD45, CD45RA, and CD45R0), compared to other cancers (lymphoma, melanoma, colon carcinoma, head and neck cancer, renal cancer, and cutaneous B-cell lymphoma), information about the antigenicity of CTCL remains relatively limited and no dependable protein marker for CTCL has been discovered.

Considering the aggressive nature of some types of CTCL, it is necessary to identify circulating molecules that can help in the early diagnosis, differentiation from inflammatory skin diseases (psoriasis, nummular eczema), and aid in predicting the prognosis and evolution of this pathology.

This review aims to bring together some of the information concerning protein markers linked to CTCL, in an effort to further the understanding of the convolute processes involved in this complex pathology.